US 2019/0169181 A1Published application

Fumagillol compounds and methods of making and using same

AssigneeZafgen, Inc.

InventorsRobert Zahler, James E. Vath

Life of this patent

Estimating the term…

Abstract

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Claims32

Dependent claims

A compound represented by Formula I:

wherein:
is a single or double bond;
R1 is selected from the group consisting of hydrogen and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one, two, or more substituents each independently selected from the group consisting of halogen, cyano, hydroxyl, and N(RbRc);
L is selected from the group consisting of a bond and —C(RL1RL2)—;
A is a 5- or 6-membered monocyclic heteroaryl ring having one, two, or three heteroatoms each independently selected from O, S, or N;
wherein A may be optionally substituted on an available carbon by a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, C1-6alkyl, C1-6alkoxy, C3-6cycloalkyl, phenyl, heterocyclyl, oxo, and —N(Rb)(Rc);
wherein C1-6alkyl, C1-6alkoxy, or C3-6cycloalkyl may optionally be substituted by one, two, three or more substituents each independently selected from the group consisting of halogen, cyano, hydroxyl, and —N(Rb)(Rc), and wherein A may be optionally substituted on an available nitrogen by Rh;
RL1 and RL2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy;
wherein C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy may optionally be substituted by one or more halogen atoms or a group selected from cyano or hydroxyl;
Ra, Rb, and Rc are each independently selected, for each occurrence, from the group consisting of hydrogen and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, and hydroxyl;
or Rb and Rc may form, together with the nitrogen to which they are attached, a 4-6 membered heterocycle;
Rh is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, and C1-6alkoxycarbonyl-, wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, and C1-6alkylcarbonyl- may optionally be substituted by one or more substituents selected from RP;
RP is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, cyano, C1-6alkoxy, and heterocyclyl;
wherein heterocyclyl has one, two or three heteroatoms each independently selected from the group consisting of O, NR′ (wherein R′ is H or C1-3alkyl) and S(O)w (wherein w is 0, 1, or 2);
wherein heterocyclyl may optionally be substituted by one, two or three substituents each independent selected from the group consisting of halogen, hydroxyl, and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one, two or three halogens;
or a pharmaceutically acceptable salt, stereoisomer, ester, or prodrug thereof.

16 more elements

A compound represented by:

wherein:
is a single or double bond;
R1 is selected from the group consisting of hydrogen and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one, two, or more substituents each independently selected from the group consisting of halogen, cyano, hydroxyl, and N(RbRc);
L is selected from the group consisting of a bond and —C(RL1RL2)—;
A is selected from the group consisting of:
wherein
Rhh is hydrogen, C1-6alkyl or —C1-3alkyl-heterocyclyl, wherein heterocycyl may optionally be substituted by a substituent selected from the group consisting of C1-3alkyl (optionally substituted by one, two, or three halogens), halogen, and hydroxyl;
R99 is heterocyclyl;
RL1 and RL2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy;
wherein C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy may optionally be substituted by one or more halogen atoms or a group selected from cyano or hydroxyl;
Ra, Rb, and Rc are each independently selected, for each occurrence, from the group consisting of hydrogen and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, and hydroxyl;
or
Rb and Rc may form, together with the nitrogen to which they are attached, a 4-6 membered heterocycle;
Rh is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, and C1-6alkoxycarbonyl-, wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, and C1-6alkylcarbonyl-may optionally be substituted by one or more substituents selected from RP;
RP is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, cyano, C1-6alkoxy, and heterocyclyl;
wherein heterocyclyl has one, two or three heteroatoms each independently selected from the group consisting of O, NR′ (wherein R′ is H or C1-3alkyl) and S(O)w (wherein w is 0, 1, or 2);
wherein heterocyclyl may optionally be substituted by one, two or three substituents each independent selected from the group consisting of halogen, hydroxyl, and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one, two or three halogens;
or a pharmaceutically acceptable salt, stereoisomer, ester, or prodrug thereof.

18 more elements

A compound selected from the group consisting of:

(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(5-amino-1,3,4-oxadiazol-2-yl)-2-methylpropyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(5-(methylamino)-1,3,4-oxadiazol-2-yl)propyl)carbamate;
(3R,4S,5 S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-2-methyl-1-(5-(methylamino)-1,3,4-oxadiazol-2-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(1H-imidazol-2-yl)-2-methylpropyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((R)-1-methylpyrrolidin-2-yl)methyl)-1H-imidazol-2-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((S)-1-methylpyrrolidin-2-yl)methyl)-1H-imidazol-2-yl)propyl)carbamate;
(3R,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-2-methyl-1-(5-(methylamino)-1,3,4-thiadiazol-2-yl)propyl)carbamate;
(3R,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(5-(methylamino)-1,3,4-thiadiazol-2-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(4H-1,2,4-triazol-3-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-2-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-2-methyl-1-(1-(((S)-1-methylpyrrolidin-3-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((R)-1-methylpyrrolidin-3-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((S)-1-methylpyrrolidin-2-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((S)-1-methylpyrrolidin-3-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((R)-1-methylpyrrolidin-2-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(2-morpholinoethyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(1-(((S)-1-(2,2-difluoroethyl)pyrrolidin-3-yl)methyl)-1H-imidazol-4-yl)-2-methylpropyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(1-(((R)-1-(2,2-difluoroethyl)pyrrolidin-3-yl)methyl)-1H-imidazol-4-yl)-2-methylpropyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(4-oxo-1,4-dihydropyridin-2-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1H-1,2,3-triazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((S)-1-methylpyrrolidin-3-yl)methyl)-1H-pyrazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(1-(((R)-1-methylpyrrolidin-3-yl)methyl)-1H-pyrazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((S)-2-methyl-1-(2-methyl-1-(((S)-1-methylpyrrolidin-3-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(6-(3,3-difluoroazetidin-1-yl)pyridin-3-yl)-2-methylpropyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-2-methyl-1-(6-morpholinopyridin-3-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-3-methyl-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)propan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-3-methyl-1-(5-oxo-2,5-dihydro-1,2,4-oxadiazol-3-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-3-methyl-1-(4H-1,2,4-triazol-3-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-1-(5-amino-1,3,4-oxadiazol-2-yl)-3-methylbutan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-3-methyl-1-(5-(methylamino)-1,3,4-oxadiazol-2-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-3-methyl-1-(5-(methylamino)-1,3,4-thiadiazol-2-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-3-methyl-1-(5-(methylamino)-1,3,4-thiadiazol-2-yl)butan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((R)-1-(5-amino-1,3,4-thiadiazol-2-yl)-3-methylbutan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(5-amino-1,3,4-thiadiazol-2-yl)-3-methylbutan-2-yl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (2-methyl-2-(1-(((R)-1-methylpyrrolidin-2-yl)methyl)-1H-imidazol-4-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl (2-methyl-2-(4H-1,2,4-triazol-3-yl)propyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-enyl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((S)-1-(1-isobutyl-1H-imidazol-4-yl)-2-methylpropyl)(methyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl ((S)-1-(6-(azetidin-1-yl)pyridin-3-yl)-2-methylpropyl)carbamate;
(3R,4S,5S,6R)-5-methoxy-4-((2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl)-1-oxaspiro[2.5]octan-6-yl((S)-1-(1-isobutyl-1H-imidazol-4-yl)-2-methylpropyl)carbamate;
and a pharmaceutically acceptable salt or stereoisomer thereof.

40 more elements

Dependencies are inferred from the claim text.

Facts

Application: 16/324,692Filed 11 Aug 2017
Priority: 11 Aug 2016
Published: 6 Jun 2019
Term ends: Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07D 413/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms:…
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
C07D 405/14
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having…:…
C07D 407/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided…

Family

Application62/373,440Us provisional application · filed 11 Aug 2016
US 2019/0169181 A1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

Building an agent or pulling many patents? Use the API or MCP server instead of scraping pages. Get an API key

patentgrep

Loading patent…

Abstract

A compound represented by Formula I:

wherein:
is a single or double bond;
R1 is selected from the group consisting of hydrogen and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one, two, or more substituents each independently selected from the group consisting of halogen, cyano, hydroxyl, and N(RbRc);
L is selected from the group consisting of a bond and —C(RL1RL2)—;
A is a 5- or 6-membered monocyclic heteroaryl ring having one, two, or three heteroatoms each independently selected from O, S, or N;
wherein A may be optionally substituted on an available carbon by a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, C1-6alkyl, C1-6alkoxy, C3-6cycloalkyl, phenyl, heterocyclyl, oxo, and —N(Rb)(Rc);
wherein C1-6alkyl, C1-6alkoxy, or C3-6cycloalkyl may optionally be substituted by one, two, three or more substituents each independently selected from the group consisting of halogen, cyano, hydroxyl, and —N(Rb)(Rc), and wherein A may be optionally substituted on an available nitrogen by Rh;
RL1 and RL2 are each independently selected from the group consisting of hydrogen, halogen, hydroxyl, C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy;
wherein C1-6alkyl, C3-6cycloalkyl, and C1-6alkoxy may optionally be substituted by one or more halogen atoms or a group selected from cyano or hydroxyl;
Ra, Rb, and Rc are each independently selected, for each occurrence, from the group consisting of hydrogen and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one or more substituents selected from the group consisting of halogen, cyano, oxo, and hydroxyl;
or Rb and Rc may form, together with the nitrogen to which they are attached, a 4-6 membered heterocycle;
Rh is independently selected for each occurrence from the group consisting of hydrogen, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, and C1-6alkoxycarbonyl-, wherein C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-6cycloalkyl, C1-6alkyl-S(O)2—, and C1-6alkylcarbonyl- may optionally be substituted by one or more substituents selected from RP;
RP is independently selected, for each occurrence, from the group consisting of halogen, hydroxyl, cyano, C1-6alkoxy, and heterocyclyl;
wherein heterocyclyl has one, two or three heteroatoms each independently selected from the group consisting of O, NR′ (wherein R′ is H or C1-3alkyl) and S(O)w (wherein w is 0, 1, or 2);
wherein heterocyclyl may optionally be substituted by one, two or three substituents each independent selected from the group consisting of halogen, hydroxyl, and C1-6alkyl;
wherein C1-6alkyl may optionally be substituted by one, two or three halogens;
or a pharmaceutically acceptable salt, stereoisomer, ester, or prodrug thereof.

16 more elements

Facts

Application

16/324,692Filed 11 Aug 2017

Priority

11 Aug 2016

Published

6 Jun 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification9 codes

C07D 413/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms:…
A61P 3/04
Drugs for disorders of the metabolism: anorexiants; Antiobesity agents
C07D 405/14
Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having…:…
C07D 407/14
Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided…